Abstract
This study exposes the potential usefulness of a new co-processed excipient, composed of alginic acid and microcrystalline cellulose (Cop AA-MCC), for the preparation of immediate drug release tablets by direct compression. Evaluation of the physical and mechanical properties as well as the disintegration behavior of Cop AA-MCC in comparison to commercial co-processed excipients (Cellactose®, Ludipress®, Prosolv® SMCC HD90 and Prosolv® ODT) and to the physical mixture of the native excipients (MCC and AA), was carried out. The obtained results illustrate the good performance of Cop AA-MCC in terms of powder flowability, tablet tensile strength, compressibility, and disintegration time. Although, this new co-processed excipient showed a slightly high lubricant sensitivity, which was explained by its more plastic than fragmentary deformation behavior, it presented a low lubricant requirement due to the remarkably low ejection force observed during compression. Compression speed and dwell time seemed not to affect significantly the tabletability of Cop AA-MCC. The study exposed evenly the performance of Cop AA-MCC compared to Prosolv® ODT, in terms of tabletability and dissolution rate of Melatonin. Cop AA-MCC presented comparable hardness, lower dilution potential, higher lubricant sensitivity, lower ejection force, and faster Melatonin’s release time than Prosolv® ODT. In summary, Cop AA-MCC exhibited interesting physical, mechanical, and biopharmaceutical properties, which demonstrate its concurrence to commercially available co-processed excipients. Furthermore, the simplicity of its composition and the scalability of its elaboration makes this multifunctional excipient highly recommended for direct compression.
Highlights
Direct compression (DC) continues being the most preferred choice of the pharmaceutical industry for the production of compressed tablets
The feeble improvement on the bulk density of Cop AA-MCC compared to the dry mixture DM can be attributed to the densification of the particles during the co-processing by wet granulation process [28]
The present work deals with the evaluation in direct compression of the functionality of a new co-processed excipient (Cop AA-MCC) in comparison to commercial co-processed excipients
Summary
Direct compression (DC) continues being the most preferred choice of the pharmaceutical industry for the production of compressed tablets This manufacturing process represents a fast and simple method that provides an effective and successful tableting operation. The excipients used for DC process need to provide multiple functionalities, such as good powder flowability, high binding ability, low friction tendency and fast disintegration capacity, in order to perform an effective tablet production. These desirable requirements are difficult to find in a single material. The use of multiple excipients in the tablet formulation could lead to some heterogeneity problems (segregation) and incompatibility issues that can occur between the active pharmaceutical ingredient (API) and the different excipients used [3,4]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.